Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02263365 · ClinicalTrials.gov registry record · Phase 3
Use of Post Operative Loperamide in Colorectal Patients After Diverting Ileostomies
A Phase 3 study, sponsored by Cedars-Sinai Medical Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT02263365 is a Phase 3 study that was terminated before completion, run by Cedars-Sinai Medical Center. The registered enrollment target is 40 participants.
The verdict
NCT02263365, a Phase 3 study, was terminated before completion, sponsored by Cedars-Sinai Medical Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
Dehydration post creation of a diverting ileostomy is a common and debilitating problem faced by patients undergoing ileal-anal pouch anastomoses for both inflammatory bowel disease and familial adenomatous polyposis (FAP) syndrome. Those patients with low rectal cancers or other polyposis syndromes e.g. HNPCC hereditary non polyposis colorectal cancers, may potentially have a delay in the adjuvant therapy when faced with this complication. Studies performed in this groups of patients report a readmission rate of 17-21% for dehydration. Loperamide has been shown to significantly decrease the daily volume of weight of stool in these patients. The purpose of this study is to establish whether loperamide given at 4mg three times daily for 14 days from day of discharge empirically decreases 30 days readmission rate for dehydration. The investigators hypothesize that there will be a 15% decrease from 25% to 10% in the readmission rates, that severity of dehydration will be decreased.
Interventions
- DRUG Loperamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2014-10-07 |
| Est. Completion | 2016-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02263365
The ClinicalTrials.gov registry entry for NCT02263365 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Loperamide is the first listed.
NCT02263365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02263365 about?
NCT02263365 is a clinical study titled "Use of Post Operative Loperamide in Colorectal Patients After Diverting Ileostomies". Dehydration post creation of a diverting ileostomy is a common and debilitating problem faced by patients undergoing ileal-anal pouch anastomoses for both inflammatory bowel disease and familial adenomatous polyposis (FAP) syndrome. Those patients with low rectal cancers or other polyposis syndromes...
What is the current status of trial NCT02263365?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2014-10-07. Estimated completion is 2016-12-31.
What interventions are being tested in trial NCT02263365?
The interventions under investigation include: Loperamide (DRUG).
Who is sponsoring clinical trial NCT02263365?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.